A Spotlight on Infectious Disease and Chronic Disease Management
A major driver of the India Rapid Diagnostics Market is the high burden of infectious and chronic diseases. Rapid diagnostics are playing an increasingly critical role in the management of these conditions by enabling quick, accurate, and accessible testing, which is essential for timely intervention and disease control. The Infectious Diseases segment is the largest application segment, holding a 36.03% revenue share in 2024, driven by a persistent need to test for prevalent conditions like dengue, malaria, tuberculosis, and hepatitis. The ability to provide an immediate diagnosis for these diseases, especially in public health camps and remote areas, is a game-changer for effective disease management. The market's role in chronic disease management is also expanding rapidly. With the number of diabetic patients set to soar, the demand for blood glucose monitors and continuous glucose monitoring (CGM) systems is immense. Companies like Abbott are actively capitalizing on this by launching advanced CGMs like the FreeStyle Libre 2 Plus, which provides continuous, real-time data that empowers patients to better manage their condition. Furthermore, the market is seeing a growing number of rapid tests for cardiometabolic markers, enabling clinicians to make rapid, life-saving decisions in emergency settings.
Link: Find out how rapid diagnostics are used for disease management
FAQs
Which diseases are major drivers? Infectious diseases like tuberculosis and dengue, as well as chronic diseases like diabetes, are the primary drivers of the market.
How do rapid tests help manage these diseases? Rapid tests allow for quick diagnosis, immediate treatment, and continuous monitoring, which is essential for effective disease management.